AOD-9604 for Sarcopenia in Older Adults: Protocol, Evidence, and Monitoring

What Is AOD-9604 and Why Is It Considered for Sarcopenia?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to residues 176-191 of human growth hormone. Researchers at Monash University initially developed it to replicate the lipolytic properties of GH without stimulating IGF-1 or promoting insulin resistance. Because sarcopenia involves not only muscle loss but also concurrent fat accumulation (sarcopenic obesity), clinicians have extrapolated its potential body-composition benefits to older adults.

The Sarcopenia Problem in Older Adults

Sarcopenia affects an estimated 10-27% of community-dwelling adults over age 65, a range confirmed by a 2019 systematic review and meta-analysis (N=58,404) published in the Journal of Cachexia, Sarcopenia and Muscle [1]. Adults lose roughly 3-8% of muscle mass per decade after age 30, with losses accelerating sharply after age 60 [2]. That muscle loss correlates directly with fall risk, hospitalization, and all-cause mortality.

The European Working Group on Sarcopenia in Older People 2 (EWGSOP2) defines sarcopenia as low muscle strength combined with low muscle quantity or quality, and classifies it as severe when physical performance is also impaired [3]. Standard interventions include resistance training and protein optimization (1.2-1.6 g/kg/day per ESPEN guidelines), but a meaningful subset of older adults cannot sustain adequate training loads due to frailty, joint disease, or fatigue [4].

Where AOD-9604 Fits

Growth hormone secretion declines approximately 14% per decade of adult life, a phenomenon sometimes called somatopause [5]. Because AOD-9604 was designed to mimic GH's fat-metabolizing properties without the mitogenic risks of full-length GH, some clinicians position it as a lower-risk adjunct to address the body-composition imbalance that makes sarcopenic obesity especially difficult to treat. The reasoning is biologically plausible, but it relies on mechanism rather than direct muscle-outcome data.

Evidence Base: What Clinical Data Actually Exist?

The honest answer is that the direct evidence for AOD-9604 in sarcopenia is thin. Most published data address obesity, not muscle preservation, and the largest trials remain unpublished or were completed under the METAOD program in the early 2000s.

METAOD Phase IIb Trial

Metabolic Pharmaceuticals conducted a randomized, double-blind, placebo-controlled Phase IIb trial (METAOD006) in overweight adults. The primary endpoint was weight loss, not muscle mass. At the 12-week mark, participants receiving AOD-9604 1 mg/day orally showed statistically significant fat mass reduction compared with placebo, though lean mass changes were not the primary reported outcome [6]. The trial was not conducted in adults over 65, and the oral formulation differs pharmacokinetically from the subcutaneous route used in contemporary compounding.

Preclinical Muscle and Metabolism Data

A 2001 study in Biochemical and Biophysical Research Communications demonstrated that the GH 177-191 fragment stimulated lipolysis in rat adipocytes via a beta-3 adrenergic mechanism independent of IGF-1 signaling [7]. A separate rodent study found that AOD-9604 administration did not raise plasma IGF-1, insulin, or glucose, suggesting a favorable metabolic safety profile at the molecular level [8]. Neither study examined skeletal muscle protein synthesis directly.

Observational and Practitioner-Level Data

Peer-reviewed observational data in older humans are absent. What exists are case series and forum-based practitioner reports, which represent the lowest tier of evidence. The FDA has not approved AOD-9604 for any indication. The agency removed it from the bulk drug substances list under 503A compounding regulations in 2015, though it continues to appear in compounded preparations [9].

AOD-9604 Protocol for Sarcopenia in Older Adults: A Clinical Framework

The following protocol synthesizes available pharmacokinetic data, practitioner consensus, and the METAOD safety profile. It is a Level III-IV framework, meaning it is built on observational data and biological plausibility rather than RCT evidence. Prescribers should document informed consent explicitly noting the absence of Phase III sarcopenia-specific data.

Candidate Selection Criteria

Before initiating AOD-9604, a clinician should confirm all of the following:

• Age 60 or older with documented sarcopenia per EWGSOP2 criteria (grip strength below 27 kg for men or 16 kg for women, plus low appendicular lean mass on DEXA) [3]
• Suboptimal response to 12 weeks of supervised resistance training at appropriate load (defined as no meaningful improvement in five-times sit-to-stand test or 4-meter gait speed)
• Fasting glucose below 126 mg/dL and HbA1c below 6.5% (AOD-9604 appears glucose-neutral in preclinical data, but baseline glycemic status must be confirmed) [8]
• No active malignancy, no personal history of hormone-sensitive cancer, no uncontrolled thyroid disease
• BMI between 22 and 35 kg/m² (below 22 raises concern for primary undernutrition that peptide therapy will not correct)

Dosing and Administration

Starting dose: 200 mcg subcutaneous injection once daily, administered in the periumbilical adipose tissue.

Timing: Early morning, fasted state, at least 30 minutes before food or other medications. Growth hormone fragments show blunted activity when insulin is elevated.

Titration: If tolerability is confirmed at 14 days with no injection-site reactions and stable fasting glucose, the dose may increase to 300 mcg daily. Some practitioners use 250 mcg as a fixed dose to avoid the sharper titration step.

Cycle length: 12 weeks on, followed by a minimum 4-week washout. Some practitioners extend to 16 weeks in adults who show gradual response on DEXA re-assessment at week 12. Continuous use beyond 16 weeks without a break is not supported by available safety data.

Combination Considerations

AOD-9604 is frequently combined with CJC-1295 (without DAC) plus Ipamorelin in frailty-focused protocols. CJC-1295/Ipamorelin stimulates endogenous GH pulses; AOD-9604 provides targeted lipolytic activity. The combination is intended to address both the muscle-anabolic and fat-redistributive components of sarcopenic obesity. Growth hormone-releasing peptides like Ipamorelin carry their own risk profile, including fluid retention and potential IGF-1 elevation, which requires separate monitoring [10].

BPC-157 at 250-500 mcg daily is sometimes added when joint pain or soft-tissue injury limits the patient's ability to engage in resistance training. BPC-157 has demonstrated accelerated tendon and ligament healing in rodent models, though human RCT data are similarly absent [11].

Testosterone replacement therapy (TRT) in hypogonadal men or hormone therapy in postmenopausal women with documented deficiency may be the higher-evidence anchor of any sarcopenia protocol. The Testosterone Trials (TTrials, N=788) showed that testosterone supplementation in men 65 and older with low testosterone (below 275 ng/dL) produced significant gains in lean mass and walking distance at 12 months [12]. AOD-9604, if used, should be considered adjunctive to these higher-evidence interventions rather than a replacement for them.

Monitoring Protocol: Labs, Imaging, and Functional Outcomes

Monitoring in older adults requires more vigilance than in younger populations. Frailty amplifies the impact of small metabolic shifts, and the absence of long-term safety data for AOD-9604 in this age group makes regular assessment mandatory.

Baseline Assessment (Before Day 1)

| Test | Rationale | |---|---| | DEXA scan (whole body) | Establishes appendicular lean mass and fat mass index | | Grip strength (dynamometer) | EWGSOP2 diagnostic criterion; functional baseline | | 4-meter gait speed or 5x sit-to-stand | Physical performance score | | Fasting glucose, HbA1c, fasting insulin | AOD-9604 is considered glucose-neutral, but baseline confirmation is necessary | | IGF-1 | Rules out acromegaly-range values before any GH-pathway intervention | | Lipid panel | Metabolic context; lipolytic agents can transiently shift FFA flux | | CBC, CMP | General safety screen in older adults | | PSA (men over 50) | Standard before any anabolic or GH-adjacent protocol |

Interim Assessment (Week 6)

A single mid-cycle check should include fasting glucose, a subjective fatigue and injection-site tolerance questionnaire, and grip strength. This visit exists primarily to catch glucose dysregulation early and to assess adherence.

End-of-Cycle Assessment (Week 12-16)

Repeat DEXA is the primary efficacy measure. A clinically meaningful change in appendicular lean mass index in older adults is approximately 0.5-1.0 kg of lean mass gained or preserved over 12 weeks, based on resistance training trial benchmarks from the SENATOR-ONTOP systematic review [13]. If lean mass is unchanged and gait speed has not improved by at least 0.1 m/s (the minimally clinically important difference established in large cohort studies [14]), the protocol should be reassessed before a second cycle is prescribed.

Safety Signals to Watch

• Edema (suggests fluid retention; may indicate off-target GH activity if combined with GH-releasing peptides)
• Fasting glucose rising above 100 mg/dL in a previously eugycemic patient
• Injection-site lipohypertrophy (rotate sites every injection)
• New or worsening fatigue (could indicate adrenal or thyroid shifts in frail older adults)

Expected Timeline of Outcomes

Practitioners using AOD-9604 in body-composition protocols report the following rough timeline based on aggregated clinical experience. These are not RCT-derived benchmarks.

Weeks 1-4: Subjective reports of reduced fatigue in some patients. No measurable body-composition change expected on DEXA. Injection tolerance should be established.

Weeks 4-8: Modest reductions in visceral fat may begin to appear on waist circumference measurement. Lean mass preservation (not gain) is the realistic target at this stage, particularly in patients who are also engaged in resistance training.

Weeks 8-12: The primary DEXA re-assessment window. In patients combining AOD-9604 with 3-4 sessions per week of progressive resistance training and adequate protein intake (at minimum 1.2 g/kg/day per ESPEN guidelines [4]), lean mass stabilization or incremental gain is the target outcome. Fat mass reduction of 1-2 kg is a plausible secondary outcome based on the lipolytic mechanism demonstrated in preclinical models [7].

Post-cycle washout (weeks 13-16 if 12-week cycle): Continue resistance training and protein targets. Reassess grip strength and gait speed at the end of washout before deciding on a second cycle.

Nutrition and Exercise: Non-Negotiable Co-Interventions

AOD-9604 cannot substitute for the interventions with the strongest evidence base in sarcopenia. Any protocol that prescribes this peptide without addressing these factors is incomplete.

Protein Intake

The ESPEN guidelines (2018) recommend 1.2-1.6 g of protein per kg of body weight per day for older adults at risk of or with sarcopenia, with an emphasis on leucine-rich sources at each meal [4]. A single meal dose of at least 2.5-3 g of leucine appears to be the threshold for maximal muscle protein synthesis stimulation in older adults, based on work by Churchward-Venne et al. Published in the American Journal of Clinical Nutrition [15].

Resistance Training

Progressive resistance training remains the single intervention with the most consistent RCT evidence for sarcopenia. A Cochrane review of 121 trials (N=6,700) found that resistance training produced significant improvements in muscle strength, gait speed, and functional performance in older adults [16]. Any peptide protocol layered on top of inadequate exercise stimulus is unlikely to produce meaningful results.

Vitamin D and Creatine

Vitamin D deficiency (serum 25-OH-D below 30 ng/mL) is present in a large proportion of older adults and directly impairs muscle function [17]. Creatine monohydrate at 3-5 g daily has shown additive benefit to resistance training for lean mass in adults over 65 in multiple RCTs [18]. Both are low-cost, high-evidence adjuncts that should be addressed before or alongside any peptide protocol.

Risk, Regulatory, and Informed Consent Considerations

AOD-9604 does not have FDA approval for any clinical indication. The FDA's 2015 decision to exclude it from the 503A bulk drug substances list limits its legal availability to certain 503B outsourcing facilities and restricts its compounding under standard pharmacy rules [9]. Prescribers operating under 503B compounding arrangements should document the medical rationale for use, the absence of an FDA-approved alternative, and explicit patient acknowledgment of the experimental nature of the treatment.

The long-term oncologic safety of AOD-9604 in older adults has not been established. While preclinical data suggest it does not raise IGF-1 (a known mitogenic signal), the absence of IGF-1 elevation in rodent studies does not guarantee the same in humans over multi-year use [8]. The American Association of Clinical Endocrinology (AACE) guidelines on growth hormone use caution that any GH-pathway intervention in older adults warrants careful individual risk-benefit analysis, particularly in patients with prior malignancy [19].

"The use of growth hormone and its fragments in older adults must be approached with caution given the incomplete long-term safety data and the potential for unintended metabolic consequences," states the Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults [20].

Prescribers should document that resistance training and protein optimization were attempted or are contraindicated before introducing AOD-9604, and that the patient understands the Level III-IV evidence grade supporting its use.